Format

Send to

Choose Destination
Cardiol Rev. 2008 Mar-Apr;16(2):59-68. doi: 10.1097/CRD.0b013e31815a6600.

Pharmacologic management of mesenteric occlusive disease.

Author information

1
Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA. William_Frishman@nymc.edu

Abstract

Mesenteric vascular disease has been diagnosed increasingly over the past 25 years. This rise in incidence has been attributed to the advanced mean age of the population, an increasing number of critically ill patients and a greater clinical recognition of the condition. Although surgical revascularization and resection has long been the standard of treatment, medical management can also play an important adjunctive role. Early diagnosis before irreversible bowel damage, which may occur within 6-8 hours after the insult, is necessary to improve survival and reduce morbidity. Even in the presence of irreversible bowel ischemia, perioperative medical treatment may reduce disease progression, enabling more limited bowel resection. This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory.

PMID:
18281907
DOI:
10.1097/CRD.0b013e31815a6600
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center